These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31921185)

  • 1. A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response.
    Marini A; Zhou Y; Li Y; Taylor IJ; Leneghan DB; Jin J; Zaric M; Mekhaiel D; Long CA; Miura K; Biswas S
    Front Immunol; 2019; 10():2931. PubMed ID: 31921185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.
    Leneghan DB; Miura K; Taylor IJ; Li Y; Jin J; Brune KD; Bachmann MF; Howarth M; Long CA; Biswas S
    Sci Rep; 2017 Jun; 7(1):3811. PubMed ID: 28630474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei.
    Yao G; Min H; Yu X; Liu F; Cui L; Cao Y
    Parasit Vectors; 2023 Nov; 16(1):403. PubMed ID: 37932796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
    King LDW; Pulido D; Barrett JR; Davies H; Quinkert D; Lias AM; Silk SE; Pattinson DJ; Diouf A; Williams BG; McHugh K; Rodrigues A; Rigby CA; Strazza V; Suurbaar J; Rees-Spear C; Dabbs RA; Ishizuka AS; Zhou Y; Gupta G; Jin J; Li Y; Carnrot C; Minassian AM; Campeotto I; Fleishman SJ; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Long CA; Miura K; Ashfield R; Skinner K; Howarth MR; Biswas S; Draper SJ
    Cell Rep Med; 2024 Jul; 5(7):101654. PubMed ID: 39019011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity.
    Chan JA; Wetzel D; Reiling L; Miura K; Drew DR; Gilson PR; Anderson DA; Richards JS; Long CA; Suckow M; Jenzelewski V; Tsuboi T; Boyle MJ; Piontek M; Beeson JG
    PLoS One; 2019; 14(9):e0221733. PubMed ID: 31504038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
    Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
    Front Immunol; 2021; 12():641421. PubMed ID: 33815393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine.
    Yenkoidiok-Douti L; Williams AE; Canepa GE; Molina-Cruz A; Barillas-Mury C
    Sci Rep; 2019 Nov; 9(1):16833. PubMed ID: 31727945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha.
    Wetzel D; Chan JA; Suckow M; Barbian A; Weniger M; Jenzelewski V; Reiling L; Richards JS; Anderson DA; Kouskousis B; Palmer C; Hanssen E; Schembecker G; Merz J; Beeson JG; Piontek M
    PLoS One; 2019; 14(9):e0221394. PubMed ID: 31483818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
    Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses.
    Sungwa M; Susan T; Mikkel JC; Adolph KR; Boniface MS; Grundtvig TT; Ali S; Agertoug NM; Frederik SA
    Afr Health Sci; 2017 Jun; 17(2):373-381. PubMed ID: 29062332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM; Miura K; Long CA; Burns JM
    PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.
    Crossey E; Frietze K; Narum DL; Peabody DS; Chackerian B
    PLoS One; 2015; 10(7):e0132560. PubMed ID: 26147502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice.
    Brod F; Miura K; Taylor I; Li Y; Marini A; Salman AM; Spencer AJ; Long CA; Biswas S
    Front Immunol; 2018; 9():2780. PubMed ID: 30564231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.